JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review

  • 0Department of Chest Disease, University of Firat, Elazig, Türkiye.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of Wasog +

|

March 18, 2025

|

March 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Lung cancer (LC) is a critical comorbidity in idiopathic pulmonary fibrosis (IPF) patients, reducing survival. Managing LC in IPF requires individualized treatment considering risks like acute exacerbation (AE) of IPF.

Area Of Science

  • Pulmonology
  • Oncology
  • Internal Medicine

Background

  • Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease.
  • Lung cancer (LC) frequently co-occurs with IPF, significantly impacting patient prognosis.
  • LC diagnosis in IPF patients leads to a reduced mean survival time.

Purpose Of The Study

  • To highlight the critical interplay between IPF and LC.
  • To emphasize the need for individualized therapeutic strategies for LC in IPF patients.
  • To underscore the importance of preventing LC in IPF management.

Main Methods

  • This study is a review of current literature on IPF and LC comorbidities.
  • Analysis of treatment risks and outcomes for LC in IPF patients.
  • Evaluation of the impact of cancer treatments on IPF exacerbations.

Main Results

  • LC diagnosis in IPF patients is associated with decreased survival rates.
  • Anticancer treatments can trigger life-threatening acute exacerbations (AE) of IPF.
  • Therapeutic options for IPF-associated LC are often limited by the risk of AE.

Conclusions

  • Management of LC in IPF necessitates tailored treatment plans accounting for individual risk.
  • Preventing LC in IPF patients is crucial due to the adverse effects of cancer and its treatment on IPF prognosis.
  • Further research is needed to optimize treatment strategies for this complex comorbidity.